→ Oncology company Bicycle Therapeutics, which has put its faith in synthetic short peptides that it believes can deliver a payload better than antibodies, has broken out the terms of its IPO. The Cambridge, United Kingdom-based company plans to offer 4.3 million American Depositary Shares (ADSs) in the price range of $14 to $16 to raise $65 million, it said in a filing on Monday. Bicycle, which was founded in 2009 and has raised $147 million in cash already, plans to list under the symbol BCYC.
→ Lilly’s $LLY cancer drug Cyramza is losing its boxed warning — highlighting the risk hemorrhage, gastrointestinal perforation and impaired wound healing — courtesy of the FDA, which also expanded the use of the drug for certain patients with hepatocellular carcinoma. This is the fifth approval for the drug for a type of advanced or metastatic cancer, which generated $821.4 million last year.
→ Vifor Pharma announced today that the primary endpoint in their Phase II AMBER study was met. The company says that the study showed that a significantly higher proportion of patients with resistant hypertension (RHTN) and chronic kidney disease (CKD) taking Veltassa (patiromer) —which enables spironolactone for blood pressure management by controlling blood potassium levels — remained on spironolactone therapy compared to patients taking placebo at week 12. The data were presented at the 2019 National Kidney Foundation (NKF) Congress in Boston, Massachusetts.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription